Table 2.
Fluoroquinolone Prescribing Based on Academic Versus Non-academic Clinic
| Outcome | Academic clinic N = 56 |
Non-academic clinic N = 160 |
P value* |
|---|---|---|---|
| Composite outcome for inappropriate prescription†, n (%) | 41 (73.2) | 152 (95.0) | < 0.001 |
| By provider, n/n (%) | |||
| Resident physician | 31/40 (77.5) | 2/2 (100) | – |
| Advanced practice provider | 1/2 (50.0) | 29/31 (93.5) | 0.209‡ |
| Attending physician | 9/14 (64.3) | 121/127 (95.3) | 0.013§ |
| Inappropriate indication, n (%) | 36 (64.3) | 138 (86.3) | < 0.001 |
| Unnecessary prescription, n (%) | 6 (10.7) | 54 (33.8) | 0.001 |
| Excessive duration, n (%) | 27 (48.2) | 104 (65.0) | 0.027 |
| Insufficient duration, n (%) | 1 (1.8) | 2 (1.3) | 1.00 |
| Inappropriate dose, n (%) | 19 (33.9) | 85 (53.1) | 0.013 |
| Bug-drug mismatch, n (%) | 2 (3.6) | 12 (7.5) | 1.000 |
| Adverse drug reaction within 30 days|, n (%) | 1 (1.8) | 5 (3.1) | 1.000 |
*< 0.05 is considered statistically significant
†The primary composite outcome was the percentage of inappropriate fluoroquinolone prescriptions classified by at least one of the following: inappropriate indication, unnecessary prescription, inappropriate duration, inappropriate dose, or bug-drug mismatch. Inappropriate indication = prescriptions for diagnoses in which fluoroquinolones are not recommended; unnecessary prescription = diagnoses with no indication for antibiotics; bug-drug mismatch = treatment of a bacterial pathogen identified on culture with intermediate or resistant susceptibility to fluoroquinolones
‡Comparison between residents and advanced practice providers
§Comparison between resident and attending
|Yeast infection (n = 2), gastrointestinal upset (n = 2), seizure (n = 1), and arthralgia (n = 1)